LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Pfizer

Geschlossen

BrancheGesundheitswesen

27.73 0.51

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

27.3

Max

27.93

Schlüsselkennzahlen

By Trading Economics

Einkommen

-5.2B

-1.6B

Verkäufe

903M

18B

KGV

Branchendurchschnitt

19.89

121.746

EPS

0.66

Dividendenrendite

6.32

Gewinnspanne

-9.387

Angestellte

81,000

EBITDA

-6.6B

-930M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+6.88% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

6.32%

2.26%

Nächstes Ergebnis

28. Apr. 2026

Nächste Dividendenausschüttung

6. März 2026

Nächstes Ex-Dividendendatum

8. Mai 2026

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

2.2B

154B

Vorheriger Eröffnungskurs

27.22

Vorheriger Schlusskurs

27.73

Nachrichtenstimmung

By Acuity

42%

58%

126 / 352 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bullish Evidence

Pfizer Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

3. Feb. 2026, 12:25 UTC

Ergebnisse

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

20. Jan. 2026, 10:40 UTC

Akquisitionen, Fusionen, Übernahmen

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments -- Update

20. Jan. 2026, 07:47 UTC

Akquisitionen, Fusionen, Übernahmen

GSK to Acquire RAPT for $2.2 Billion to Bolster Food Allergy Treatments

10. Feb. 2026, 21:51 UTC

Ergebnisse

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

10. Feb. 2026, 21:17 UTC

Ergebnisse

Gilead Earnings Surprise. Why The Stock Is Tumbling Anyway. -- Barrons.com

3. Feb. 2026, 21:36 UTC

Ergebnisse

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3. Feb. 2026, 19:56 UTC

Ergebnisse

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3. Feb. 2026, 19:46 UTC

Ergebnisse

These Stocks Are Today's Movers: Palantir, Pfizer, AMD, PayPal, Novo Nordisk, PepsiCo, Merck, and More -- Barrons.com

3. Feb. 2026, 17:35 UTC

Ergebnisse

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3. Feb. 2026, 17:30 UTC

Ergebnisse

These Stocks Are Today's Movers: Palantir, PayPal, Novo Nordisk, Pfizer, Merck, AMD, Gartner, and More -- Barrons.com

3. Feb. 2026, 13:50 UTC

Ergebnisse

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3. Feb. 2026, 13:06 UTC

Ergebnisse

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3. Feb. 2026, 12:45 UTC

Ergebnisse

These Stocks Are Today's Movers: Palantir, PayPal, Teradyne, Tesla, Pfizer, AMD, Merck, and More -- Barrons.com

3. Feb. 2026, 12:02 UTC

Ergebnisse

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street. -- Barrons.com

3. Feb. 2026, 11:48 UTC

Ergebnisse

Pfizer: About 20 Key Pivotal Study Starts Planned for 2026 >PFE

3. Feb. 2026, 11:48 UTC

Ergebnisse

Pfizer: Enters 2026 With Clear Strategic Priorities, Growing Late-Stage Pipeline >PFE

3. Feb. 2026, 11:47 UTC

Ergebnisse

Pfizer: Current Financial Guidance Doesn't Anticipate Any Stock Buybacks in 2026 >PFE

3. Feb. 2026, 11:46 UTC

Ergebnisse

Pfizer Sees 2026 Adjusted R&D Expenses $10.5B-$11.5B >PFE

3. Feb. 2026, 11:45 UTC

Ergebnisse

Pfizer Reaffirms 2026 Guidance >PFE

3. Feb. 2026, 11:45 UTC

Ergebnisse

Pfizer 4Q Rev $17.56B >PFE

3. Feb. 2026, 11:45 UTC

Ergebnisse

Pfizer Sees FY Adj EPS $2.80-Adj EPS $3.00 >PFE

3. Feb. 2026, 11:45 UTC

Ergebnisse

Pfizer 4Q Adj EPS 66c >PFE

3. Feb. 2026, 11:45 UTC

Ergebnisse

Pfizer 4Q Loss/Shr 29c >PFE

3. Feb. 2026, 11:45 UTC

Ergebnisse

Pfizer 4Q Loss $1.65B >PFE

3. Feb. 2026, 11:45 UTC

Ergebnisse

Pfizer Sees FY Rev $59.5B-$62.5B >PFE

3. Feb. 2026, 10:41 UTC

Ergebnisse

These Stocks Are Today's Movers: Palantir, Teradyne, Tesla, AMD, NXP Semiconductors, DaVita, and More -- Barrons.com

20. Jan. 2026, 07:13 UTC

Akquisitionen, Fusionen, Übernahmen

GSK PLC: Agreement Simplifies ViiV's Shareholder Structure

20. Jan. 2026, 07:13 UTC

Akquisitionen, Fusionen, Übernahmen

GSK PLC to Get Special Div of $0.250B

20. Jan. 2026, 00:21 UTC

Akquisitionen, Fusionen, Übernahmen

Shionogi to Acquire Additional Shares in ViiV Healthcare for $2.1B

12. Jan. 2026, 21:18 UTC

Market Talk

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

Peer-Vergleich

Kursveränderung

Pfizer Prognose

Kursziel

By TipRanks

6.88% Vorteil

12-Monats-Prognose

Durchschnitt 28.91 USD  6.88%

Hoch 35.46 USD

Tief 25 USD

Basierend auf 18 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Pfizer – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

18 ratings

6

Buy

12

Halten

0

Sell

Technischer Score

By Trading Central

22.855 / 23.85Unterstützung & Widerstand

Kurzfristig

Bullish Evidence

Mittelfristig

Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

126 / 352 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Pfizer

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as has strategic clinical collaboration with Acepodia Inc. for the development of antibody-cell conjugation-based cell therapies in autoimmune diseases. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
help-icon Live chat